YouSub
Untitled

en English

Untitled English subtitles

0 downloads · 236 lines · added Aug 12, 2015

Report a problem
What's wrong?
Advertisement

English transcript

Biochemistry 401 Lecture 33 Today we’re going to talk about nucleotide function,
structure and synthesis. We’re going to talk about the de novo pathway, and
the salvage pathway. So let’s get started.
Let's begin by talking about nucleotide function. Nucleotides are precursors for nucleic acid
synthesis, DNA and RNA, and this is what we primarily think about what we think about
nucleotides, but they’re also used for energy sources. ATP is a prime energy source for
biological processes such as molecular motors and active transport of solutes across membranes.
GTP is also sometimes used as an energy source. Nucleotides can also activate biomolecules
for synthetic reactions, and we’ve seen this previously, for instance UTP activating
glucose and CTP activating alcohol head groups, and we've also seen ATP activating many biomolecules.
Nucleotides and their derivatives are also important parts of many of many second messenger
systems, such as cyclic AMP and cyclic GMP. Finally, ATP is a source of phosphate for
kinase reactions, such as the ones that are involved in regulation. We saw this in glycogen
synthesis and degradation, and also in glycolysis, and so nucleotides serve many diverse functions.
So now let's talk about structure. We’re going to talk about structure of nucleosides first.
Nucleosides are comprised of two things, sugars and nitrogenous bases. Ribonucleosides
are comprised of a ribose sugar and a base, and deoxyribonucleosides are comprised of
a deoxyribose sugar and a base, and the difference is shown here. We have adenosine that’s
shown in the top figure and deoxyadenosine that’s shown in the bottom figure. The difference
between the two is that deoxyadenosine is reduced at the two prime position, and the
arrow is pointing to this position. Now the bases can either be purines or pyrimidines,
and we’ll see that in just a minute.
Nucleotides are nucleosides plus 1, 2 or 3 phosphates. In the top position we see adenosine
a nucleoside, and in the bottom position we see adenosine monophosphate, AMP. This is
also known as adenylate.
In this slide, we see the nomenclature of bases, nucleosides, and nucleotides.
It's important that you know the name of the base, the name of the ribonucleoside or deoxyribonucleoside,
and the name of the ribonucleotide, or deoxyribonucleotide. And so it's important that you know the difference
between adenosine and adenylate, for instance.
Nitrogenous bases fit into two major categories. Purines consist of adenine and guanine, and
if you’ll notice, these are structures made up of two rings. Pyrimidines have one ring,
and there are three of them, Cytosine, uracil and thymine. To remember this, here are some
mnemonics, pure as gold for purines A and G, cut pie, C, U, T are all pyrimidines.
I hope this helps. So now let’s look at nucleotide synthesis.
There are two major pathways. The first is the salvage pathway, in which we use recycled
bases and attach them to an activated ribose platform, PRPP, which is 5-phosphoribosyl-1-pyrophosphate.
The other way is the de novo pathway and this is making bases from scratch. We start with
an activated ribose again, PRPP, and we add amino acids, ATP, carbon dioxide, and other
things to make the finished nucleotide.
So in the salvage pathway, 5-phosphoribosyl-1-pyrophosphate plus guanine for instance, yields guanosine
monophosphate and pyrophosphate, and so this is driven forward by the pyrophosphate release
and subsequent hydrolysis to two molecules of inorganic phosphate.
The de novo pathway is little more complex, and pyrimidines and purines use two different
strategies. Pyrimidine rings are simple, they’re formed first, and they’re brought to the
activated ribose platform PRPP, and the subsequent progression, involving several steps, is first
to make UTP and then to make CTP. These are both ribonucleotides that can be used to make RNA.
Then UTP is used to make TMP and CTP is used to make dCTP. These are both deoxyribonucleotides.
And so what we do first is we make the base first, we attach it to PRPP and then we make ribonucleotides.
We use the ribonucleotides as substrates to make deoxyribonucleotides.
Now purines are much more complex. They involve two rings. These are made directly on the
PRPP platform, first to make the intermediate IMP, then to make ATP and GTP. So, we’re
making ribonucleotides first and then to dATP and dGTP to make deoxyribonucleotides.
Purine rings are formed piece by piece right on the activated ribose sugar.
We're going to go over the primitive de novo pathway first as an overview and then we’re
going to go through it bit by bit. We're going to do this with the pyrimidine de novo pathway,
but were not going to do the same thing with the purine de novo pathway. So let's get started with this.
First of all we’re going to synthesize an intermediate called orotate. This is comprised
of carbamoyl phosphate and aspartate. We’re then going to form orotidylate. This occurs
by attaching orotate to PRPP. Then were going to form UMP, uridylate. This happens through
a decarboxylation of orotidylate and then we’re going to phosphorylate UMP to make
UTP, and then were going to aminate UTP to make CTP and these are all ribonucleotides.
The next that’s going to happen, we're going to make TPP and dCTP. We're going to start with orotate synthesis,
So the first thing we’re going to do is we’re going to make orotate, and it looks like this.
The green portions come from aspartate, and the blue and black portions come from
carbamoyl phosphate. Now that's a name that should seem familiar to you.
This is the synthesis of carbamoyl phosphate. The process is essentially the same as what
we saw when we looked at the urea cycle. Carbamoyl phosphate synthetase II actually catalyzes
the rate-limiting step in pyrimidine de novo synthesis, and so it's really important that
you understand this process. This is the cytosolic enzyme that synthesizes carbamoyl phosphate.
Do you remember where the other carbamoyl phosphate synthetase was? The one that's involved
in urea synthesis is actually in the mitochondrion. This one, that's involved in nucleotide synthesis,
is found in the cytosol. And so, just like before, we're going to start with bicarbonate.
We're going to phosphorylate it to make carboxy phosphate. We’re then going to aminate it
to form carbamic acid, then another phosphorylation to yield carbamoyl phosphate. And so this
is an activated intermediate.
And this is where the difference comes in. If you’ll remember, in urea synthesis,
the amino group came from ammonium. In this case however, the amino group can either come from
ammonium, or it can come from glutamine. We’re going to see that glutamine is often a donor
of amino groups, and so what we have is glutamine plus carbon dioxide plus two ATPs plus water yields
carbamoyl phosphate plus glutamate plus two ADP plus inorganic phosphate, and the water that
you see there is used in the hydrolysis of glutamine to make glutamate. Now, if you look
at the enzyme here it looks similar to the one that we saw in the urea cycle, but there's
a glutamine hydrolysis site at the top. There's a bicarbonate phosphorylation site just below
it, and then there's a carbamic acid phosphorylation site below that.
And so again this enzyme works by channeling, and this diminishes the loss of substrate
by diffusion, and it also helps to prevent nonproductive reactions such as the hydrolysis
of ATP, which would be a waste.
And so, in the end, we have carbamoyl phosphate. This combines with aspartate and inorganic
phosphate is lost. We end up with carbamoyl aspartate, and then through hydrolysis we
end up with dihydroorotate and then there's an oxidation to make orotate.
And so we’re going to add orotate to PRPP to make orotidylate.
It is going to be added to 5-ribosyl-1-pyrophosphate, PRPP through the formation of a glycosidic bond.
This is going to be accomplished with the loss of pyrophosphate, which acts as a
leaving group. This reaction is driven forward through the subsequent hydrolysis of pyrophosphate
to yield two molecules of inorganic phosphate. The enzyme that catalyzes this reaction is
called for pyrimidine phosphoribosyltransferase, and this name makes sense.
We’re transferring a pyrimidine ring to a phosphoribosyl platform to yield orotidylate.
The next step is the decarboxylation of orotidylate to yield uridylate, UMP. This is accomplished
through the loss of the carboxylic acid group that was originally part of the aspartate
R-group, and finally again, we end up with carbon dioxide and uridylate. We're almost there. We have UMP.
Now to go from uridylate to UTP, there are two kinase reactions that occur to go from
UMP to UDP to UTP and there are specific kinases that do that. We won't go into this in too much detail,
but the next thing that happens is we’re going to add an amino group from glutamine,
which is a really good amino group donor. And so, first we’re going to phosphorylate,
and then we’re going to hydrolyze the amino group from glutamine and transfer it to UTP
to make CTP. And so the process of going from UTP to CTP is an amination.
Control of pyrimidine synthesis occurs through the regulation of two enzymes, primarily,
those are carbamoyl phosphate synthetase and aspartate transcarbamoylase.
We're going to look at each of these individually.
So let's start with carbamoyl phosphate synthetase. This enzyme functionality catalyzes the rate-limiting
step of pyrimidine synthesis, and so is very important. This functionality is inhibited by UTP.
Now this is the product of the pathway and so this is product inhibition. It's also known as negative feedback.
This enzyme functionality is activated by PRPP, which is one of the substrates in UMP synthesis.
Aspartate transcarbamoylase is negatively regulated by its product, CTP and it is positively
regulated by ATP, which is a purine. Now this makes sense. CTP will negatively feed back
on this pathway to ensure that too many pyrimidines are not made, whereas ATP will increase the
activity of aspartate transcarbamoylase to ensure that when there are too many purines
around and not enough pyrimidines that more pyrimidines are made. It's important to remember
that a stable base pair requires both pyrimidines and purines, and so therefore, we must have
relatively equal amounts of pyrimidines and purines, to make RNA or to make DNA.
We’re now going to talk about the de novo synthesis of purines. This is a more complex
synthetic pathway, and so we’re just going to hit the high points. So, let's talk about
the big picture first. We’re going to make an intermediate inosine monophosphate, IMP.
This is going to be used to further make ATP and GTP, which can be used for RNA, and then
these can be reduced to make dATP and dGTP. This synthesis begins with phosphoribosylamine synthesis.
This reaction is catalyzed by the enzyme glutamine phosphoribosylamine.
This represents the first committed step in the de novo synthesis of purines. The amino group
is going to be hydrolyzed from glutamine, and then the ammonia is going to be added
to PRPP with the loss of pyrophosphate. That is then hydrolyzed to two molecules of inorganic
phosphate, and so we’re left with five-phosphoribosyl-1-amine and two molecules of inorganic phosphate.
This is the first committed step, and therefore it is highly regulated. This reaction, like
many of the reactions in nucleotide synthesis, is regulated by downstream products.
This enzyme is inhibited by AMP and ADP and by GMP and GDP.
And here are the next steps. You'll be happy to know that you do not need to know these
steps at all. In fact we're going to go straight from phosphoribosylamine all the way to the
next major intermediate, and this is an inosinate. This is a common intermediate in both the
synthesis of AMP and GMP and inosinate is also called inosine monophosphate, IMP.
IMP has a hypoxanthine base. Now the difference between AMP and IMP, and the difference between
GMP and IMP, is the presence of an additional amino group. In the synthesis of AMP,
we're going to replace the ketone with an amino group. In the synthesis of GMP, we’re going
to add another ketone and then aminate that, to make GMP. In each case, we’re going to
phosphorylate to activate the molecules them we can add an amino group. Let's look at this
a little more closely.
The synthesis of AMP and GMP occur through a branched synthesis from IMP.
One branch gives rise to AMP, and the other one gives rise to GMP, and so inosine monophosphate
is a common intermediate in the formation of both of these nucleotides.
We're going to talk about the synthesis of AMP first. We’re going to start with IMP, and then
we’re going to phosphorylate it and add an amino group from aspartate that we have
a little bit extra that's included in the intermediate adenylosuccinate, and we’re
going to release that little bit as fumrate and we end up with adenylate, AMP. I want
to draw your attention to the fact they we’re using GTP as a phosphate source in the synthesis
of AMP, and the reason for this will become clear in just a minute. Now in the other branch,
in the synthesis of GMP from IMP, we’re going to make the extra ketone first, to make
xanthylate, we’re then going to phosphorylate xanthylate, and then we’re going to hydrolyze
an amino group from glutamine to make glutamate, and free ammonia. The ammonia is going to
be added to make GMP. We’re using ATP in this phosphorylation, and so for this synthesis,
you need to know what the common intermediate is. You need to know what the final products are.
You need to know what the phosphate donor is and what the amino donor is for each of these synthetic branches.
Now the overall control of purine synthesis has four distinct points of regulation.
Each of these is inhibited by downstream products. The synthesis of PRPP itself is inhibited
by IMP AMP GMP, and also by GDP and ADP. These are the downstream products of this reaction,
and the same is true for the synthesis of phosphoribosylamine as we saw just a minute ago.
Now the thing is, if you inhibit the synthesis of PRPP itself, you’re also going
to inhibit the synthesis of histidine and pyrimidine nucleotides. On the other hand,
if you inhibit the synthesis of phosphoribosylamine you're going to just limit the production
of IMP, AMP and GMP. Now if we look at the branches going from IMP to AMP, or to GMP,
We’ll notice that AMP feeds back to inhibit the synthesis of AMP and GMP feeds back to
inhibit its synthesis. Now this offers a means of regulating this branched pathway so that
high concentrations of AMP turn down the production of AMP and allow GMP to catch up. If we inhibit
the top branch, the bottom branch will be used. Likewise, if we inhibit the bottom branch,
the top branch will be used and will make more AMP. In this way we get relatively equal
amounts of AMP and GMP, and this is why we use different nucleoside triphosphates as
phosphate sources in this syntheses. The production of AMP relies on GTP as a phosphate source
and the synthesis of GMP relies on ATP as a phosphoryl source. if this were reversed, we'd have big trouble.
So now we're going to talk about the salvage pathway this is of prime importance for the synthesis of purines.
The salvage pathway relies on phosphoribosy transferases, abbreviated PRT.
These attach a preformed base that can be scavenged either from endogenous nucleotide
breakdown, or from the breakdown of dietary nucleotides. We scavenge the base, and we
add it to the activated ribose platform, PRPP. The transferases are specific for the types
of bases that they attach, and there are two major purine base transferases. The first
one transfers just adenine. So adenine plus PRPP yields adenosine monophosphate, plus
pyrophosphate, and of course we’re going to hydrolyze the pyrophosphate to make two
molecules of inorganic phosphate, and this is what's going to drive the reaction forward.
Now guanine and hypoxanthine bases are both transferred by the same enzyme, HGPRT, hypoxanthine
guanine phosphoribosyl transferase. Guanine or hypoxanthine are added to PRPP to make
GMP or IMP and pyrophosphate, and again, these are driven forward by the hydrolysis of pyrophosphate
to two molecules of inorganic phosphate. By which, uracil and thymine bases are scavenged.
Now a defect in HG PRT leads to Lesch-Nehyan syndrome, and this is a pretty profound syndrome.
It arises through X-linked recessive mutation. Individuals that have this, have differing
degrees of problems. This syndrome leads to uncontrolled severe movement, also referred
to as spasticity severe mental deficiency, in some cases self-mutilation including biting
the fingers off, or biting the lips or tongue, severe hyper-aggression, and severe gout,
and also kidney stones. A loss of HGPRT results in both an increase in serum PRPP and also
an increase in serum urate, which is the catabolism product of purine bases. This increase in
serum urate gives rise to gout and kidney stones, and because the salvage pathway is
not working, there is an increase in the purine de novo synthesis.
Deoxynucleotides are made from ribonucleoside diphosphate. We're going to reduce the 2’ hydroxyl
and then we’re going to phosphorylate the diphosphate to make a triphosphate.
The exception to this is the production of TTP. This requires a folate derivative, and a special pathway.
For this, we need deoxyuridyl monophosphate dUMP, and the cofactor N5-N10-methylene-tetrahydrofolate.
This cofactor is a folate, vitamin B9, derivative. This is going to transfer a methyl group to
deoxyuridylate, to make thymidylate, and so the products of this reaction are TMP and
dihydrofolate, in the process of this reaction, N5-N10-methylene-tetrahydrofolate is converted
to dihydrofolate. For this enzyme to become active again, we must reconstitute N5-N10-methylene-tetrahydrofolate,
and to do this are going to use the enzyme tetrahydrofolate reductase.
This is going to reduce dihydrofolate to tetrahydrofolate, and we’re going to use electrons from an
NADPH to do this. Once we have tetrahydrofolate, we’re going to use a methyl group from serine
to regenerate N5-N10-methylene-tetrahydrofolate. So, since this cycle is used in the production
of TMP, and not any of the ribonucleotides, if we target this cycle, we can shut down
DNA synthesis, and so potent chemotherapeutics are used for this. Fluorouracil is a suicide
inhibitor. It binds in the active site of thymidylate synthase and serves to shut it
down by making covalent bond to the enzyme that can't be broken. So you can knock out
thymidylate synthase. Other chemotherapeutics, include aminopterine and methotrexate. These
serve to inhibit the dihydrofolate reductase, because they look a lot like dihydrofolate,
and so they can compete for the active site, and so aminopterine and methotrexate are competitive
inhibitors of dihydrofolate reductase.
Folic acid is necessary for the production of thymidylate. We take in folic acid in the diet.
We cannot make folic acid. However, bacteria can make folic acid, and one of the
things they use to make folic acid is PABA. This is an aminobenzoate. In order to block
folic acid production in bacteria, we can use sulfa drugs, These are antibiotics that
look a lot like PABA. Sulfonamide is shown and you can see the similarity in structure.
Sulfonamide can act as a competitive inhibitor of the enzyme that makes folic acid.
So by blocking folic acid production, we can block thymidylate production, and thereby block
replication in bacteria.
The enzyme that catalyzes the reduction of the 2’ prime hydroxyl is ribonucleotide
reductase, and we’re not going discuss this enzyme in great detail. It’s sufficient
to know that it has an active site and allosteric sites in each of the monomers that make up this dimer.
This enzyme is primarily regulated through allostery, and one of the major ways
in which this enzyme is regulated is through the actions of ATP to activate and dATP to deacti
…

Need subtitles from another video?